As the Regulatory Agency, which Biokinetica Early Phase Institute is subject to remains fully mobilised to deliver fast-track assessments, it has significantly shortened the timeframes for review and registration of Clinical Trial Applications for new medicines targeting COVID-19.
The RA accelerated the evaluation and approval path to the maximum of 3 weeks (or 5 weeks in case of a deficiency letter).
